Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

d the drug exhibited good dose proportionality. Alexza and Symphony Allegro are also developing Staccato loxapine (AZ-004) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.

About Symphony Allegro

In December 2006, Alexza entered into a collaboration with Symphony Capital LLC, a biotech-focused private equity firm. Under the terms of the agreement, Alexza and Symphony Capital established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato alprazolam (AZ-002) and Staccato loxapine (AZ-004 and AZ-104). Alexza has granted a license to the intellectual property for the selected product candidates. Through a purchase option, Alexza retains the exclusive right, but not the obligation, to acquire 100% of the equity of Symphony Allegro at specified prices during the term of the agreement. If Alexza chooses not to exercise the purchase option, Symphony Allegro retains the rights to the product candidates. The term of the agreement is up to four years.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in New York on ... . Dr. Helen Torley , President and Chief ... presentation will be webcast through the "Investors" section of Halozyme,s ... be made available for 90 days following the event. To ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Feb. 23, 2012  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX® in ... today announced that its partner Auxilium Pharmaceuticals, Inc. ... Pharmaceuticals Ltd. (Actelion) for the long-term development, supply ...
... Feb. 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2011 ... virus (HCV) development pipeline. Operational ...
Cached Medicine Technology:BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 2BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 3BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8
(Date:11/26/2014)... DC (PRWEB) November 26, 2014 For ... (AIS) independently published The AIS Report on Blue Cross ... and WellPoint, Inc. on the varied strategies the two ... and improve compliance with treatments for sleep apnea, ranging ... sleep disorder, because it’s linked to increased rates of ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance for elder ... the adult demographic education and access to computer ... rough seas of applying for Medicaid. Part of this ... of Medicaid eligibility and proper planning, while also helping ... this coverage. , Senior Planning Services has made ...
(Date:11/26/2014)... California (PRWEB) November 26, 2014 Medical ... of 3.9 out of 5. This score represents steady ... the three years to 2014 as a result of ... medical suction machines, which are largely considered nondiscretionary. IBISWorld ... purchasing process, buyers have some degree of flexibility, given ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer ... Preceptorship Award from The American Association of ... advancement of nurse practitioners. The Distinguished Preceptorship Award ... made a significant contribution toward increasing the awareness ... Nurse Practitioners (AANP) is the largest full-service national ...
(Date:11/26/2014)... -- The number of emergency department visits in the United ... record 136 million in 2011, according to the U.S. Centers ... that fewer people were going to ERs with non-urgent medical ... care within two hours of arriving at the ER. In ... Sixty percent of patients arrived at the ER after ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:ER Visits on the Rise, Study Reports 2
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... Cream 0.1%, a generic version of,VANOS(R) Cream 0.1%. The ... an,ANDA with a Paragraph IV certification against VANOS(R)., ... to relieve the inflammation and itching caused by certain,skin ...
... suggest current dietary requirements need to be increased , , MONDAY, ... the risk of heart attack in men, says a U.S. ... and Brigham and Women,s Hospital, Boston, analyzed medical records and ... had a nonfatal heart attack or fatal heart disease, and ...
... Francisco, Calif., June 07, 2008 Results from ... announced today at the American Diabetes Association (ADA) ... Development Center, Inc. Alogliptin, which has been ... dipeptidyl peptidase-4 (DPP-4), is currently under investigation as ...
... June 9 The Department of,Labor & Industry invites the ... the 10th annual Health & Safety Day from 10 a.m. ... Wing Rotunda in,Harrisburg., The event will feature an array ... home. Visitors to the event can,receive - free of charge ...
... wheel, with 2.2% reporting accidents as result , , MONDAY, June ... of sleep may be a real problem for American college ... at the University of North Texas found that 17 percent ... that group reported having accidents because of this drowsiness. A ...
... College of Physicians (ACP) today pledged its support for ... Patients and Providers Act of 2008. , "The College ... addresses and incorporates three of our top legislative priorities," ... Max Baucus (D-MT), chairman of the Senate Finance Committee. ...
Cached Medicine News:Health News:Perrigo Confirms Filing for Generic Version of VANOS(R) 2Health News:Phase 3 results for alogliptin 2Health News:Phase 3 results for alogliptin 3Health News:Sleepy Driving Prevalent Among Collegians 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: